L
Lara Kidoguchi
Researcher at University of Washington
Publications - 25
Citations - 3905
Lara Kidoguchi is an academic researcher from University of Washington. The author has contributed to research in topics: Pre-exposure prophylaxis & Serodiscordant. The author has an hindex of 12, co-authored 22 publications receiving 3329 citations.
Papers
More filters
Journal ArticleDOI
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Jared M. Baeten,Deborah Donnell,Deborah Donnell,Patrick Ndase,Nelly Mugo,Nelly Mugo,James D. Campbell,Jonathan Wangisi,Jordan W. Tappero,Elizabeth A. Bukusi,Craig R. Cohen,Elly Katabira,Allan R. Ronald,Allan R. Ronald,Elioda Tumwesigye,Edwin Were,Kenneth H. Fife,James Kiarie,James Kiarie,Carey Farquhar,Grace John-Stewart,Aloysious Kakia,Josephine Odoyo,Akasiima Mucunguzi,Edith Nakku-Joloba,Rogers Twesigye,Kenneth Ngure,Cosmas Apaka,Harrison Tamooh,Fridah Gabona,Andrew Mujugira,Dana Panteleeff,Katherine K. Thomas,Lara Kidoguchi,Meighan Krows,Jennifer Revall,Susan Morrison,Harald S. Haugen,Mira Emmanuel-Ogier,Lisa Ondrejcek,Robert W. Coombs,Lisa M. Frenkel,Lisa M. Frenkel,Craig W. Hendrix,Namandjé N. Bumpus,David R. Bangsberg,Jessica E. Haberer,Wendy S. Stevens,Jairam R. Lingappa,Connie Celum +49 more
TL;DR: Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women, and both study medications significantly reduced the HIV- 1 incidence among both men andWomen.
Journal ArticleDOI
Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa
Jessica E. Haberer,Jared M. Baeten,James D. Campbell,Jonathan Wangisi,Elly Katabira,Allan R. Ronald,Elioda Tumwesigye,Christina Psaros,Steven A. Safren,Norma C. Ware,Katherine K. Thomas,Deborah Donnell,Deborah Donnell,Meighan Krows,Lara Kidoguchi,Connie Celum,David R. Bangsberg,David R. Bangsberg +17 more
TL;DR: The association between high adherence to antiretroviral pre-exposure prophylaxis and HIV transmission in a substudy of serodiscordant couples participating in a clinical trial is investigated.
Journal ArticleDOI
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
Jared M. Baeten,Renee Heffron,Lara Kidoguchi,Nelly Mugo,Nelly Mugo,Elly Katabira,Elizabeth A. Bukusi,Elizabeth A. Bukusi,Stephen Asiimwe,Jessica E. Haberer,Jennifer F Morton,Kenneth Ngure,Nulu Bulya,Josephine Odoyo,Edna Tindimwebwa,Craig W. Hendrix,Mark A. Marzinke,Norma C. Ware,Monique A. Wyatt,Susan Morrison,Harald S. Haugen,Andrew Mujugira,Deborah Donnell,Deborah Donnell,Connie Celum +24 more
TL;DR: Integrated delivery of time-limited PrEP until sustained ART use in African HIV-1-serodiscordant couples was feasible, demonstrated high uptake and adherence, and resulted in near elimination of HIV- 1 transmission, with an observed HIV incidence of <0.5% per year compared to an expected incidence of >5%" per year.
Journal ArticleDOI
Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
Jairam R. Lingappa,Jared Baeten,Anna Wald,James P. Hughes,Katherine K Thomas,Andrew Mujugira,Nelly Mugo,Elizabeth A. Bukusi,Elizabeth A. Bukusi,Craig R. Cohen,Elly Katabira,Allan R. Ronald,James Kiarie,Carey Farquhar,Grace John Stewart,Joseph Makhema,Myron Essex,Edwin Were,Kenneth H. Fife,Guy de Bruyn,Glenda Gray,James McIntyre,Rachel Manongi,Saidi Kapiga,David Coetzee,Susan Allen,Mubiana Inambao,Kayitesi Kayitenkore,Etienne Karita,William Kanweka,Sinead Delany,Helen Rees,Bellington Vwalika,Amalia Magaret,Amalia Magaret,Richard S. Wang,Lara Kidoguchi,Linda E Barnes,Renee Ridzon,Lawrence Corey,Lawrence Corey,Lawrence Corey,Connie Celum +42 more
TL;DR: The role of suppression of herpes simplex virus type 2 in reduction of HIV-1 disease progression before initiation of antiretroviral therapy warrants consideration.
Journal ArticleDOI
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial
Jared M. Baeten,Deborah Donnell,Deborah Donnell,Nelly Mugo,Nelly Mugo,Patrick Ndase,Katherine K. Thomas,James D. Campbell,Jonathan Wangisi,Jordan W. Tappero,Elizabeth A. Bukusi,Craig R. Cohen,Elly Katabira,Allan R. Ronald,Allan R. Ronald,Elioda Tumwesigye,Edwin Were,Kenneth H. Fife,James Kiarie,James Kiarie,Carey Farquhar,Grace John-Stewart,Lara Kidoguchi,Robert W. Coombs,Craig W. Hendrix,Mark A. Marzinke,Lisa M. Frenkel,Lisa M. Frenkel,Jessica E. Haberer,David R. Bangsberg,Connie Celum +30 more
TL;DR: The results do not rule out the potential for a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabine plus ten ofovirdisioproxilfumarate, but show that once-daily oral tenofavir disOProxilFumarate or emticitabines plus tenofogel fumarine regimens both provide high protection against HIV- 1 acquisition in heterosexual men and women